Dianosic: Funding, Investors & Team (Sep 2026)
Dianosic was established in 2017 and creates cutting-edge solutions for the $50 billion, double-digit-growing, and still mostly untapped ENT (Ear, Nose, and Throat) sector. Due of the enormous prospects for drug-device combinations in this area, our startup is located exactly at the intersection of medical technology and pharmaceuticals. The ENT Department at the University Hospital of Strasbourg is where the initiative started, and there are unmet clinical requirements there. Chronic rhinitis, chronic sinusitis, and intranasal haemorrhage are our primary emphasis areas (Epistaxis) It's noteworthy that Dianosic has a sizable French and German manufacturing presence. With its drug-eluting Active Resorbable Scaffold, Dianosic's strategic objective is to establish new standards of care for chronic rhinitis and chronic sinusitis (ARIS)
Dianosic has raised $6.5M across 2 funding rounds on record, the most recent a Seed of $5.0M announced in Feb 2023.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Dianosic Company Profile and Key Stats
Latest funding round on record: Feb 2023.
Dianosic Funding Rounds
Dianosic raised $1.5M in an undisclosed round announced in Apr 2020.
2.8 years later, a Seed of $5.0M was announced in Feb 2023.
Dianosic Founders and Leadership Team
Contact details for the Dianosic team: 1 of 1 has an email address on file.
Start 14-day free trial →Dianosic Funding Compared to Other Biotechnology Startups
Dianosic's latest round of $5.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Dianosic in Biotechnology and Strasbourg
Companies Similar to Dianosic
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
Dianosic Funding FAQs
What does Dianosic do?
Dianosic was established in 2017 and creates cutting-edge solutions for the $50 billion, double-digit-growing, and still mostly untapped ENT (Ear, Nose, and Throat) sector. Due of the enormous prospects for drug-device combinations in this area, our startup is located exactly at the intersection of medical technology and pharmaceuticals. The ENT Department at the University Hospital of Strasbourg is where the initiative started, and there are unmet clinical requirements there. Chronic rhinitis, chronic sinusitis, and intranasal haemorrhage are our primary emphasis areas (Epistaxis) It's noteworthy that Dianosic has a sizable French and German manufacturing presence. With its drug-eluting Active Resorbable Scaffold, Dianosic's strategic objective is to establish new standards of care for chronic rhinitis and chronic sinusitis (ARIS)
How much funding has Dianosic raised?
Dianosic has raised $6.5M across 2 rounds on record. The most recent is a Seed of $5.0M announced in Feb 2023.
When did Dianosic last raise funding?
Dianosic's most recent funding round on record is a Seed of $5.0M, announced in Feb 2023.
Who is the CEO of Dianosic?
Philippe Bastide is listed as CEO at Dianosic.
Where is Dianosic headquartered?
Dianosic is based in Strasbourg, Alsace, France.
How many employees does Dianosic have?
Dianosic is in the 11-50 employee band.
How does Dianosic's funding compare to other Biotechnology startups?
Dianosic's latest round of $5.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Dianosic Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Dianosic is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.